1,2-二-O-十四烷基-sn-甘油-3-磷酸胆碱 | 36314-48-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 中文名称: 1,2-二-O-十四烷基-sn-甘油-3-磷酸胆碱
• 中文别名: 1,2-十四烷基卵磷脂
• 英文名称: 1,2-di-O-tetradecyl-sn-glycero-3-phosphocholine
• 英文别名: 1,2-DI-O-Tetradecyl-SN-glycero-3-phosphatidylcholine；[(2R)-2,3-di(tetradecoxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 36314-48-4
• 化学式: C₃₆H₇₆NO₆P
• 分子量: 649.976
• InChiKey: DAYFLFDXFQCPCQ-PSXMRANNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.1
• 重原子数：
  44
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  77
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  Xylitol 、 1,2-二-O-十四烷基-sn-甘油-3-磷酸胆碱 在 enzyme phospholipase D 作用下， 以 乙醚 为溶剂， 反应 20.0h， 生成 1,2-dimyristyl-phosphatidylxylitol
  参考文献：
  名称：

  [EN] METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING RESPIRATORY RELATED DISEASES AND CONDITIONS WITH XYLITOL-HEADGROUP LIPID ANALOGS
  [FR] PROCÉDÉS ET COMPOSITIONS POUR TRAITER ET PRÉVENIR DES MALADIES ET D'AFFECTIONS LIÉES À LA RESPIRATION AVEC DES ANALOGUES DE LIPIDE DE GROUPE DE TÊTE XYLITOL

  摘要：

  本发明一般涉及通过向个体施用至少一种木糖醇脂质类似物或包含至少一种木糖醇脂质类似物的组合物来预防和/或抑制病毒感染以及抑制炎症和/或病原体感染的方法。本发明还涉及通过向个体施用至少一种木糖醇脂质类似物或包含至少一种木糖醇脂质类似物的组合物来预防或抑制呼吸道合胞病毒(RSV)感染的方法。

  公开号：

  WO2018157107A1

文献信息

• Liposomal formulation of nonglycosidic ceramides and uses thereof
  申请人：LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.

  公开号：US10039715B2

  公开（公告）日：2018-08-07

  The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.

  本发明提供了在其双层内含有非糖苷类神经酰胺的脂质体及其组合物。这些脂质体可在体外和体内激活小鼠 iNKT 细胞并诱导树突状细胞（DC）成熟，其功效与相应的可溶性非糖苷神经酰胺相当。此外，还提供了使用本发明脂质体和组合物治疗疾病的方法。
• Lytic peptide biosensor and methods of making and using the same
  申请人：Deetex, LLC

  公开号：US10858398B2

  公开（公告）日：2020-12-08

  The presently disclosed subject matter is directed to an assay that detects and quantitatively determines the activity of a lytic peptide that exhibits antimicrobial activity, such as LL-37. Particularly, the assay comprises inducing and/or transfecting bacteria to produce high levels of an enzyme, such as β-galactosidase. The bacteria are then preserved by lyophilization. After a desired amount of time, the bacteria are hydrated with a target sample from a subject suspected of having a specific disease or disorder characterized by an increase in levels of lytic peptide. In the presence of lytic peptide, the enzyme is released from the interior of the bacteria, which can then be detected by alteration of the enzyme substrate. In the absence of lytic peptide, the enzyme remains within the bacteria and no detection of the enzyme occurs.

  目前公开的主题涉及一种检测方法，该方法可检测并定量确定具有抗菌活性的裂解肽（如 LL-37）的活性。特别是，该检测方法包括诱导和/或转染细菌以产生高水平的酶（如 β-半乳糖苷酶）。然后通过冻干法保存细菌。经过一定时间后，将细菌与目标样本水合，目标样本来自疑似患有特定疾病或失调的受试者，其特征是溶菌肽水平升高。在存在溶菌肽的情况下，酶会从细菌内部释放出来，然后可以通过酶底物的改变来检测。在没有溶菌肽的情况下，酶会留在细菌内部，无法检测到酶。
• Method and apparatus for assaying a drug candidate to estimate a pharmacokinetic parameter associated therewith
  申请人：——

  公开号：US20020019019A1

  公开（公告）日：2002-02-14

  A method and apparatus for assaying a drug candidate with a biosensor having one or more sensing surface-bound biomolecules associated therewith are disclosed. The method comprises the steps of measuring the binding interaction between the drug candidate and the one or more sensing surface-bound biomolecules of the biosensor to obtain an estimate of at least one binding interaction parameter of the drug candidate, and then comparing the estimated binding interaction parameter against a mathematical expression correlated from binding interaction data associated with known drug compounds to determine an estimate of at least pharmacokinetic parameter of absorption, distribution, metabolism, or excretion (ADME) that is related to the drug candidate. The present invention allows for the simultaneous measurement of different pharmacokinetic parameters of the drug candidate, as well as an indication of the drug candidate's solubility, by use of a single analytical instrument. The pharmacokinetic data may be represented as a ADME characterization profile; such ADME profiles are of great utility for purposes of drug screening and lead optimization.

  本发明公开了一种用生物传感器检测候选药物的方法和装置，该生物传感器具有一个或多个与之相关的传感表面结合生物分子。该方法包括以下步骤：测量候选药物与生物传感器的一个或多个传感表面结合的生物分子之间的结合相互作用，以获得候选药物的至少一个结合相互作用参数的估计值，然后将估计的结合相互作用参数与与已知药物化合物相关的结合相互作用数据相关的数学表达式进行比较，以确定与候选药物相关的至少一个吸收、分布、代谢或排泄（ADME）药动学参数的估计值。本发明允许使用一台分析仪器同时测量候选药物的不同药代动力学参数以及候选药物的溶解度。药代动力学数据可表示为 ADME 特征曲线；这种 ADME 曲线对药物筛选和先导物优化非常有用。
• METHOD AND APPARATUS FOR ASSAYING A DRUG CANDIDATE TO ESTIMATE A PHARMACOKINETIC PARAMETER ASSOCIATED THEREWITH
  申请人：Biacore AB

  公开号：EP1188058B1

  公开（公告）日：2005-05-11
• LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF
  申请人：Ludwig Institute for Cancer Research, Ltd.

  公开号：EP2654779B1

  公开（公告）日：2018-02-28